Moderna Inc. shares slid 3.5% on Friday as unease mounted about the biotech’s Covid-19 vaccine trial fueled by ongoing insider shares sales and an enrollment slowdown.
Moderna said its experimental coronavirus vaccine induced immune responses in people aged 56 years and older that were comparable to those seen in younger adults in a small study.
Nearly a fifth of 11,000 people enrolled so far in a 30,000-volunteer U.S. trial testing a COVID-19 vaccine from Pfizer and German partner BioNTech are Black or Latino, groups among the hardest hit by the coronavirus virus pandemic, a top Pfizer executive said.
(AP) — Who gets to be first in line for a COVID-19 vaccine? U. S. health authorities hope by late next month to have some draft guidance on how to ration initial doses, but it’s a vexing decision. “Not everybody’s going to like the answer,” Dr. Francis Collins, director of the National Institutes of Health, recently told one of the advisory groups the government asked to help decide. “There will be many people who feel that they should have been at the top of the list. ”
The race to develop a COVID-19 vaccine is heating up globally and right here in our area. In Seattle, we’ve got a lot of companies and volunteers doing their part to try and help. “It’s been 16 weeks since I had the first dose," said Jennifer Haller of Ballard. "I feel fantastic. " On March 16, Haller, a 43-year-old a tech startup operations manager, became the first person in the country to get injected with the experimental COVID-19 vaccine.
Stocks moved higher to start the third quarter.
Moderna’s development of a successful Sars-Cov-2 vaccine would validate the company’s technology and expand its platform, says Piper Sandler analyst Ted Tenthoff.
Germany has authorised its first clinical test of a vaccine for the novel coronavirus, the country's regulatory body said Wednesday, green-lighting trials on human volunteers for an RNA vaccine developed by German firm Biontech and US giant Pfizer.